Alnylam Pharmaceuticals Inc (ALNY)vsBiomarin Pharmaceutical Inc (BMRN)
ALNY
Alnylam Pharmaceuticals Inc
$303.05
-0.19%
HEALTHCARE · Cap: $37.76B
BMRN
Biomarin Pharmaceutical Inc
$56.77
+0.53%
HEALTHCARE · Cap: $10.81B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 32% more annual revenue ($4.29B vs $3.24B). ALNY leads profitability with a 12.6% profit margin vs 8.3%. ALNY appears more attractively valued with a PEG of 0.48. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
BMRN
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.4%
Fair Value
$2372.19
Current Price
$303.05
$2069.14 discount
Margin of Safety
+65.7%
Fair Value
$175.57
Current Price
$56.77
$118.80 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 37.6x book value
2.8% revenue growth
ROE of 4.3% — below average capital efficiency
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : BMRN
The strongest argument for BMRN centers on Altman Z-Score, Debt/Equity, PEG Ratio. PEG of 0.69 suggests the stock is reasonably priced for its growth.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 70.9x leaves little room for execution misses.
Bear Case : BMRN
The primary concerns for BMRN are Revenue Growth, Return on Equity, Piotroski F-Score. A P/E of 40.3x leaves little room for execution misses.
Key Dynamics to Monitor
ALNY profiles as a growth stock while BMRN is a value play — different risk/reward profiles.
ALNY carries more volatility with a beta of 0.27 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
BMRN generates stronger free cash flow (200M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 55/100) and 96.4% revenue growth. BMRN offers better value entry with a 65.7% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Biomarin Pharmaceutical Inc
HEALTHCARE · BIOTECHNOLOGY · USA
BioMarin Pharmaceutical Inc. develops and markets therapies for people with rare diseases and serious and life-threatening medical conditions. The company is headquartered in San Rafael, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?